Portfoliotracker

BioVersys AG

BIOV.SW · SWISS · Healthcare Biotechnology 18/100 E

22,80 CHF
▼ −0,20 (−0,87 %)
Closed delayed by 15 min
Price as of 17. 11. 17:16, fetched 17. 11. 17:44
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score18 / 100 Market cap129 mil. CHF P/E– Forward P/E-4,0 P/S80,7 P/B2,9 EV/EBITDA– Dividend yield– FCF yield-19,98 % EPS-4,50 CHF Net margin0,0 % Return on equity-46,0 % Beta– Debt / equity0,49
52-week range 21,20 to 30,70
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.

Employees
38
Country
Switzerland
Data since
6. 2. 2025

Explore further

Similar companies MOLN.SWKURN.SWGALD.SWBSLN.SWHUBN.SW

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account